Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

NCT01992159 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01992159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01992159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2012
Completion date
June 17, 2015
Enrollment
252 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis (pmo)